argenx ADR saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an upgrade from 88 to 91.
This proprietary rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against all other stocks in our database.
Decades of market research shows that the best stocks typically have an RS Rating north of 80 as they begin their biggest runs.
Here Are 3 Keys For Successful Stock Investing
The IBD 50 stock has risen more than 5% past a 554.74 entry in a first-stage flat base, meaning it's now out of a proper buy range. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The company posted 0% EPS growth last quarter. Sales rose 73%.
argenx ADR holds the No. 8 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
